March 5, 2009 – MDS Nordion, a leading provider of medical isotopes and radiopharmaceuticals, will showcase an improved administration system for TheraSphere, Yttrium-90 Microsphere (Y-90), a targeted internal radiation therapy for patients with inoperable, primary liver cancer, during the upcoming Society of Interventional Radiology 2009 (SIR 2009) scientific meeting in San Diego, CA.

The enhancements to the administration system allow for safer, faster and more efficient administration of TheraSphere, providing better treatment delivery for patients.

The simplified design of the administration system makes TheraSphere even easier to use for physicians. It has fewer parts, is easier to assemble, requires less handling, and reduces set-up time for physicians by approximately 50 per cent.

The disposable tubing and tubing connections have been re-designed to minimize barriers and optimize the fluid pathway, which is significant for delivery of small particle technology. These improvements optimize dose delivery, providing enhanced safety and ease of use for both medical staff and patients.

"Overall, MDS Nordion incorporated smart enhancements to facilitate the safe and effective delivery of TheraSphere including optimizing access to the dose vial and improving the overall internal flow of the therapy to the affected cells," said David Wood, M.D., chief of Interventional Radiology, Banner Good Samaritan Medical Center, Phoenix, AZ. "These upgrades make the administration of TheraSphere to our patients safer and easier."

May Wahab, M.D., associate professor of Radiation Oncology, Department of Radiation Oncology, Sylvester Cancer Center, Miller School of Medicine at University of Miami Hospital said that TheraSphere is the result of advanced technology allowing incorporation of radiation-emitting Yttrium into glass microbeads.

"The improvements made to the administration system will make delivering TheraSphere much easier and far more efficient and is an exciting development (for the medical community)," noted Dr. Wahab.

For more information: www.mdsnordion.com


Related Content

News | Radiopharmaceuticals and Tracers

Jan. 29, 2026 — The American Society for Radiation Oncology (ASTRO) has launched a national program creating Authorized ...

Time January 30, 2026
arrow
News | Radiation Oncology

Jan. 27, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading ...

Time January 29, 2026
arrow
News | PET Imaging

Jan. 26, 2026 — Nuclidium, a clinical-stage radiopharmaceutical company developing a proprietary copper-based ...

Time January 27, 2026
arrow
News | Radiology Imaging

Jan. 21, 2026 — Cathpax, a spin-off of the Lemer Pax group that designs, develops and commercializes team-wide, full ...

Time January 22, 2026
arrow
News | Radiation Therapy

Jan. 16, 2026 — Elekta has announced that its Elekta Evo* CT-Linac has received 510(k) clearance from the U.S. Food and ...

Time January 16, 2026
arrow
News | Radiopharmaceuticals and Tracers

Dec. 11, 2025 — Telix Pharmaceuticals Ltd. has announced a strategic clinical collaboration with Varian, a Siemens ...

Time December 11, 2025
arrow
News | Women's Health

Nov. 3, 2025 — —A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 ...

Time November 04, 2025
arrow
Feature | Kyle Hardner

Radiotherapy contributes to about 40% of all cancer cures but still lags behind systemic therapy in funding and ...

Time October 21, 2025
arrow
News | Prostate Cancer

Sept. 26, 2025 — A new fast and convenient approach to scintigraphy-based monitoring allows physicians to efficiently ...

Time October 03, 2025
arrow
News | Radiopharmaceuticals and Tracers

Sept. 20, 2025 — A promising new PET tracer can visualize a protein that is commonly overexpressed in triple-negative ...

Time September 18, 2025
arrow
Subscribe Now